Diagnostic and Prognostic Value of11C-Methionine PET for Nonenhancing Gliomas

• DOI: 10.3174/ajnr.a4460
• Publication Date: 2015-09-18T08:44:43Z
• Authors: K. Takano; M. Kinoshita; H. Arita; Y. Okita; Y. Chiba; N. Kagawa; Y. Fujimoto; H. Kishima; Y. Kanemura; M. Nonaka; S. Nakajima; E. Shimosegawa; J. Hatazawa; N. Hashimoto; T. Yoshimine
• Keywords: Grading (engineering)

<h3>BACKGROUND AND PURPOSE:</h3> Noninvasive radiologic evaluation of glioma can facilitate correct diagnosis and detection malignant transformation. Although positron-emission tomography is considered valuable in the care patients with gliomas, ¹⁸F-fluorodeoxyglucose ¹¹C-methionine have reportedly shown ambiguous results terms grading prognostication. The present study compared diagnostic prognostic capabilities diffusion tensor imaging, FDG, PET nonenhancing gliomas. <h3>MATERIALS METHODS:</h3> Thirty-five consecutive newly diagnosed, histologically confirmed gliomas that underwent both FDG were retrospectively investigated (23 grade II 12 III gliomas). Apparent coefficient, fractional anisotropy, tumor-to-normal tissue ratios between Prognostic values these parameters also tested by using progression-free survival. <h3>RESULTS:</h3> Grade showed significantly higher average maximum tumor2-to-normal than (<i>P</i> = .013, <i>P</i> .0017, respectively), but not FDG-PET imaging. There was no significant difference ADC, minimum anisotropy. ratio 2.0 most suitable for detecting among (sensitivity, 83.3%; specificity, 73.9%). Among receiving any adjuvant therapy, median survival 64.2 ± 7.2 months &lt;2.0 18.6 6.9 &gt;2.0 .0044). <h3>CONCLUSIONS:</h3> holds promise World Health Organization could offer a imaging biomarker